注册号: Registration number: |
ChiCTR-IPR-15007396 |
最近更新日期: Date of Last Refreshed on: |
2015-11-15 |
注册时间: Date of Registration: |
2015-11-04 |
注册号状态: |
补注册 |
Registration Status: |
Retrospective registration |
注册题目: |
注射用益气复脉(冻干)治疗冠心病心力衰竭急性加重期的多中心、随机、对照评价研究 |
Public title: |
Assessment of Complementary Treatment with Yiqi Fumai Lyophilized Injection on Acute Decompensated Ischemic Heart Failure: a Multicenter, Randomized, Controlled Trial |
注册题目简写: |
|
English Acronym: |
|
研究课题的正式科学名称: |
慢性心力衰竭病证结合干预的疗效研究 |
Scientific title: |
Study on the efficacy of interventions for chronic heart failure syndroms |
研究课题代号(代码): Study subject ID: |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
申请注册联系人: |
唐娥 |
研究负责人: |
毛静远 |
Applicant: |
E Tang |
Study leader: |
Jingyuan Mao |
申请注册联系人电话: Applicant telephone: |
+86 13820599175 |
研究负责人电话: Study leader's telephone: |
+86 022-27432019 |
申请注册联系人传真 : Applicant Fax: |
+86 022-27432019 |
研究负责人传真: Study leader's fax: |
+86 022-27432019 |
申请注册联系人电子邮件: Applicant E-mail: |
521tange@163.com |
研究负责人电子邮件: Study leader's E-mail: |
jymao@126.com |
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
申请注册联系人通讯地址: |
天津市南开区鞍山西道314号 |
研究负责人通讯地址: |
天津市南开区鞍山西道314号 |
Applicant address: |
314 West Anshan Road, Nankai District, Tianjin, China |
Study leader's address: |
314 West Anshan Road, Nankai District, Tianjin, China |
申请注册联系人邮政编码: Applicant postcode: |
300193 |
研究负责人邮政编码: Study leader's postcode: |
300193 |
申请人所在单位: |
天津中医药大学第一附属医院 |
||
Applicant's institution: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
是否获伦理委员会批准: |
是 |
||
Approved by ethic committee: |
Yes |
||
伦理委员会批件文号: Approved No. of ethic committee: |
TYLL2015[K]字004 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
批准本研究的伦理委员会名称: |
天津中医药大学第一附属医院伦理委员会 |
||
Name of the ethic committee: |
Ethic Committee of First Teaching Hospital of Tianjin University of Traditional Chinese medicine |
||
伦理委员会批准日期: Date of approved by ethic committee: |
2015-09-21 | ||
伦理委员会联系人: |
|
||
Contact Name of the ethic committee: |
|
||
伦理委员会联系地址: |
|
||
Contact Address of the ethic committee: |
|
||
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
研究实施负责(组长)单位: |
天津中医药大学第一附属医院 |
||||||||||||||||||||||
Primary sponsor: |
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine |
||||||||||||||||||||||
研究实施负责(组长)单位地址: |
天津市南开区鞍山西道314号 |
||||||||||||||||||||||
Primary sponsor's address: |
314 West Anshan Road, Nankai District, Tianjin, China |
||||||||||||||||||||||
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
经费或物资来源: |
“十二五”国家科技支撑计划 |
||||||||||||||||||||||
Source(s) of funding: |
"12.5" Project of China |
||||||||||||||||||||||
研究疾病: |
冠心病心衰 |
||||||||||||||||||||||
Target disease: |
Ischemic heart failure |
||||||||||||||||||||||
研究疾病代码: |
|
||||||||||||||||||||||
Target disease code: |
|
||||||||||||||||||||||
研究类型: |
干预性研究 |
||||||||||||||||||||||
Study type: |
Interventional study |
||||||||||||||||||||||
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
Study phase: |
4 |
||||||||||||||||||||||
研究目的: |
在西药规范治疗的基础上加载注射用益气复脉(冻干):1.进一步降低冠心病心力衰竭急性加重期患者的血浆BNP水平2.降低冠心病心力衰竭急性加重期患者2个月病死率和再住院率 |
||||||||||||||||||||||
Objectives of Study: |
For further reduction of BNP levels and 2-month mortality and readmission rates in acute decompensated ischemic heart failure patients by complementary treatment with Yiqi Fumai Lyophilized Injection. |
||||||||||||||||||||||
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
研究设计: |
随机平行对照 |
||||||||||||||||||||||
Study design: |
Parallel |
||||||||||||||||||||||
纳入标准: |
1.年龄40-79岁;2.明确冠心病病史;3.符合慢性心力衰竭急性加重期诊断标准;4.NYHA心功能分级Ⅲ~Ⅳ级;5.BNP>200pg/ml;6.符合气阴两虚中医辨证标准;7.签署知情同意书。 |
||||||||||||||||||||||
Inclusion criteria |
1. Aged 40 to 79; 2. Patients with coronary heart disease; 3. Patients with acute decompensated chronic heart failure; 4. Cardiac function classification: New York Heart Association (NYHA) III to IV; 5. Those whose Brain Natriuretic Peptide(BNP)>200pg/mL; 6. Patients with Qi-yin deficiency syndrome; 7. Signed informed consent. |
||||||||||||||||||||||
排除标准: |
1.首诊急性心力衰竭者;2.有下列疾病之一者:a.急性冠脉综合征;b.低血压(收缩压﹤90mmHg);c.心源性休克;d.药物难以控制的高血压(收缩压≥180mmHg和/或舒张压≥110mmHg);e.Ⅱ度Ⅱ型以上窦房或房室传导阻滞未置入起搏器治疗、难以控制的恶性心律失常;f.严重瓣膜疾病;g.扩张型心肌病;h.肥厚梗阻性心肌病;i.心肌炎;j.肺动脉栓塞;k.肺心病;l.近6个月内脑卒中者等;3.近2月内计划行血运重建术或CRT治疗的患者;4.肝功能谷丙转氨酶>3倍ULN(正常值上限)者;5.血清肌酐>2倍ULN(正常值上限)者;6.甲亢等严重内分泌疾病者;7.血红蛋白≤9g/dl者;8.精神病患者;9.恶性肿瘤患者;10.妊娠或计划妊娠者,哺乳期妇女;11.对研究药物可疑或明确过敏;12.近2月内参加其他研究者。 |
||||||||||||||||||||||
Exclusion criteria: |
1. Those who suffer from acute heart failure on initial diagnosis; 2. Those who have one of the following diseases: 1) Acute coronary syndrome; 2) Hypotension (systolic blood pressure<90mmHg); 3) Cardiogenic shock; 4) Uncontrolled high blood pressure (systolic blood pressure>=180mmHg and/or diastolic blood pressure>=110mmHg); 5) Degree II typeII or severe sinoatrial or atrioventricular block without pacemaker implantation, uncontrolled malignant arrhythmia; 6) Severe valve disease; 7) Dilated cardiomyopathy; 8) Hypertrophic obstructive cardiomyopathy; 9) Myocarditis; 10) Pulmonary embolism; 11) Pulmonary heart disease; 12) Stroke within 6 months; 3. Preparation for revascularization or cardiac resynchronization therapy (CRT) within 2 months; 4. Alanine aminotransferase(ALT)>3 times the upper limit of normal; 5. Serum creatinine>2 times the upper limit of normal; 6. Severe endocrine diseases such as hyperthyroidism, etc; 7. Hemoglobin(HB)<=9g/dl; 8. Mental disorder; 9. History of malignant tumor; 10. Being pregnant, planning for pregnancy or breastfeeding; 11. Suspicious or definite allergy to intervention drugs; 12. Participated in other trials within 2 months. |
研究实施时间: Study execute time: |
从From2015-09-01至To 2017-12-31 |
征募观察对象时间: Recruiting time: |
从From2015-09-01至To 2017-02-28 |
干预措施: Interventions: |
|
研究实施地点: Countries of recruitment and research settings: |
|
测量指标: Outcomes: |
|
采集人体标本:
Collecting sample(s)
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
性别: |
男女均可 |
Gender: |
Both |
||||||
随机方法(请说明由何人用什么方法产生随机序列): |
采用中央随机化管理系统(以下简称:IWRS)进行随机分组,将患者按1:1的比例随机分配到两组中的任一组别。当患者符合纳入/排除标准后,研究者通过网络登录到IWRS,按照系统提示输入相应纳排信息,生成患者身份识别码(SSID);根据身份识别码,对患者的心功能分级、年龄、性别等分层因素进行选择,随机系统为受试者分配唯一的随机编码及相应组别信息 |
||||||||
Randomization Procedure (please state who generates the random number sequence and by what method): |
Once the patient is included, the researcher will enter the Interactive Web Response System (IWRS) to randomization |
盲法: |
|
Blinding: |
|
试验完成后的统计结果(上传文件): |
|
Calculated Results after
|
|
是否共享原始数据: IPD sharing |
否No |
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |